Clinical Trial Update: An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases [Phase 1]

View source ↗

Summary

This is a Phase I open-label, dose-escalation study of EDB-102 evaluating safety, tolerability, and preliminary efficacy in EGFR L858R-mutant, third-generation …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EDB-102

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer | Phase 1 | Status: NOT_YET_RECRUITING